Duke spinout Istari Oncology has collected $43.5m out of a targeted $70m for its latest round.

Istari Oncology, a US-based biotechnology spinout of Duke University, has secured $43.5m out of a targeted $70m, according to a regulatory filing.
Founded in 2015, Istari Oncology is working on a therapy for bladder cancer that uses a modified poliovirus. The spinout had its application for an investigational new drug approved by the Food and Drug Administration yesterday.
The spinout is also running ongoing trials for immunotherapies aimed at recurrent glioblastoma and refractory melanoma.
Istari secured $1.1m from undisclosed backers in June 2017, having already obtained $4m four months earlier.

Thierry Heles

Thierry Heles is the former editor-at-large of Global University Venturing and Global Corporate Venturing, and was the producer and host of the Beyond the Breakthrough podcast until December 2024.